Research
Hormonal
Ghrelin stimulates food intake and growth hormone release primarily through the vagus nerve and hypothalamic pathways (NPY/AgRP neurons), rather than solely by crossing the blood-brain barrier.
This mechanism suggests that gut health and vagal nerve integrity may influence hunger signals. While not directly actionable for most, it highlights that hunger signals are complex neural communications, not just simple blood chemistry.
GoodSupportsHIGH confidence
Vagotomy inhibits the ability of ghrelin to stimulate food intake and GH release... These results indicate that the vagus afferent nerve is the major pathway conveying peripheral signals of ghrelin for starvation and GH secretion to the brain.
Why this rating
Supported by multiple studies cited in the review, including vagotomy experiments.
Source
Biological, Physiological, and Pharmacological Aspects of Ghrelin
Hiroshi Hosoda et al. · Journal of Pharmacological Sciences · 2006
DOI 10.1254/jphs.crj06002x
narrative_reviewCited 203×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Ghrelin is an endogenous peptide hormone that stimulates food intake and growth hormone secretion, with its circulating levels inversely correlated with energy balance (increasing during fasting/starvation and decreasing during feeding/obesity).Good
- Gastric bypass surgery reduces circulating ghrelin levels significantly, which may contribute to weight loss by suppressing appetite, although the mechanism is not fully understood.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →